Catumaxomab is a bispecific monoclonal antibody that targets both the epithelial cell adhesion molecule (EpCAM) and CD3, a component of the T-cell receptor complex. This unique dual-targeting capability allows Catumaxomab to facilitate the recruitment and activation of T-cells to tumor cells expressing EpCAM, thereby enhancing the immune response against cancer. It is primarily used in the treatment of malignant ascites, a condition often associated with advanced cancer, where it helps to reduce fluid accumulation in the abdominal cavity. Catumaxomab is administered intraperitoneally and has been shown to improve patient outcomes in specific clinical settings. The drug's mechanism of action involves bridging T-cells to tumor cells, leading to T-cell-mediated cytotoxicity. As a therapeutic agent, it is important to monitor for potential side effects, which may include cytokine release syndrome and other immune-related reactions. Overall, Catumaxomab represents a novel approach in cancer immunotherapy, leveraging the body's immune system to target and eliminate cancer cells.

Catumaxomab

509077-98-9: Catumaxomab is a bispecific monoclonal antibody that targets both the epithelial cell adhesion molecule (EpCAM) and CD3, a component of the T-cell receptor complex. This unique dual-targeting capability allows Catumaxomab to facilitate the recruitment and activation of T-cells to tumor cells expressing EpCAM, thereby enhancing the immune response against cancer. It is primarily used in the treatment of malignant ascites, a condition often associated with advanced cancer, where it helps to reduce fluid accumulation in the abdominal cavity. Catumaxomab is administered intraperitoneally and has been shown to improve patient outcomes in specific clinical settings. The drug's mechanism of action involves bridging T-cells to tumor cells, leading to T-cell-mediated cytotoxicity. As a therapeutic agent, it is important to monitor for potential side effects, which may include cytokine release syndrome and other immune-related reactions. Overall, Catumaxomab represents a novel approach in cancer immunotherapy, leveraging the body's immune system to target and eliminate cancer cells.

<p>Catumaxomab is a rat-mouse hybrid lgG2 monoclonal and bispecific antibody that binds to the antigens CD3 and EpCAM for malignant ascites in cancer patients.</p>

<p>A rat-mouse hybrid monoclonal antibody which binds to antigens CD3 and EpCAM.</p>

CAS 509077-98-9

Catumaxomab

Catumaxomab

Ref: TM-T78307

Catumaxomab

Ref: 3D-CLA1168